Izalontamab brengitecan (iza-bren) is an antibody-drug conjugate and bispecific antibody undergoing evaluation in small cell ...
First-line zongertinib showed antitumor activity in treatment-naive patients with advanced or metastatic HER2-mutant ...
MedPage Today on MSN
'Amazing' Results With Drug Combo in Metastatic Cervical Cancer
Combination with investigational antibody-drug conjugate showed encouraging antitumor acti ...
The Phase II cohort analysis included 145 patients whose conditions had progressed following initial chemotherapy.
Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.
SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...
Trastuzumab pamirtecan, a HER2-targeted antibody-drug conjugate, achieved ‘exceptional’ antitumor responses in patients with recurrent endometrial cancer, especially those with HER2 IHC 3+ tumors.
Recurrent/metastatic EC has a poor long-term prognosis, and treatment options are limited beyond first line, said Pothuri.
A new national cohort study provides important insights into the treatment of multidrug-resistant tuberculosis (MDR-TB). The ...
The fight for two tumor types is poised to intensify, with BioNTech lining up a challenge to AstraZeneca, while SynOx Therapeutics is planning to enter a market served by companie ...
GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...
Lung cancer is the deadliest cancer—but early screening can save lives. A survivor’s story and expert insight show why ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results